JP2008504289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504289A5 JP2008504289A5 JP2007518346A JP2007518346A JP2008504289A5 JP 2008504289 A5 JP2008504289 A5 JP 2008504289A5 JP 2007518346 A JP2007518346 A JP 2007518346A JP 2007518346 A JP2007518346 A JP 2007518346A JP 2008504289 A5 JP2008504289 A5 JP 2008504289A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- substitution
- amino acid
- alanine
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58318404P | 2004-06-25 | 2004-06-25 | |
| US62415304P | 2004-11-02 | 2004-11-02 | |
| PCT/US2005/022738 WO2006004663A2 (en) | 2004-06-25 | 2005-06-24 | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008504289A JP2008504289A (ja) | 2008-02-14 |
| JP2008504289A5 true JP2008504289A5 (https=) | 2008-07-31 |
Family
ID=35783288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518346A Withdrawn JP2008504289A (ja) | 2004-06-25 | 2005-06-24 | 部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060019342A1 (https=) |
| EP (1) | EP1773391A4 (https=) |
| JP (1) | JP2008504289A (https=) |
| AU (1) | AU2005259992A1 (https=) |
| CA (1) | CA2572133A1 (https=) |
| WO (1) | WO2006004663A2 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006045110A2 (en) * | 2004-10-18 | 2006-04-27 | Medimmune, Inc. | High cell density process for growth of listeria |
| JP5153613B2 (ja) | 2005-03-18 | 2013-02-27 | メディミューン，エルエルシー | 抗体のフレームワーク・シャッフル |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| WO2007142325A1 (ja) | 2006-06-08 | 2007-12-13 | Chugai Seiyaku Kabushiki Kaisha | 炎症性疾患の予防または治療剤 |
| TWI422594B (zh) * | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| NZ579257A (en) * | 2007-02-23 | 2011-05-27 | Baylor Res Inst | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1) |
| US20110189734A1 (en) * | 2007-08-14 | 2011-08-04 | Taylor Alexander H | Novel methods and cell lines |
| AU2008304748C1 (en) | 2007-09-26 | 2014-06-12 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| CN101874042B9 (zh) * | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2708532C (en) | 2007-12-05 | 2018-06-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-il31ra antibody and use thereof |
| CN104162155A (zh) | 2007-12-05 | 2014-11-26 | 中外制药株式会社 | 搔痒症治疗药 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI599577B (zh) * | 2008-09-26 | 2017-09-21 | Chugai Pharmaceutical Co Ltd | Methods to alter the isoelectric point of antibodies using amino acid substitutions of CDR regions |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
| CA2764377C (en) * | 2009-06-10 | 2018-03-27 | Stephen Sanig Research Institute Ltd. | Methods of generating cells exhibiting phenotypic plasticity |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| PH12012500843A1 (en) * | 2009-11-04 | 2019-07-10 | Merck Sharp & Dohme | Engineered anti-tslp antibody |
| JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
| PH12016502073B1 (en) | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| CN112812184A (zh) | 2011-02-25 | 2021-05-18 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
| TW202237660A (zh) | 2012-08-24 | 2022-10-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| CN106659774A (zh) | 2014-05-16 | 2017-05-10 | 贝勒研究院 | 用于治疗自身免疫和炎性病症的方法和组合物 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| CN114773470A (zh) * | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| JP6130983B2 (ja) | 2015-02-27 | 2017-05-17 | 中外製薬株式会社 | Ｉｌ−６関連疾患治療用組成物 |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| KR20170134748A (ko) | 2015-04-14 | 2017-12-06 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| CN108368166B (zh) | 2015-12-28 | 2023-03-28 | 中外制药株式会社 | 提高含fc区多肽纯化效率的方法 |
| US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| MA44780A (fr) | 2016-04-28 | 2019-03-06 | Chugai Pharmaceutical Co Ltd | Préparation contenant un anticorps |
| TWI693940B (zh) | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Ｉｌ-８相關疾病之治療用或預防用組成物 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| CN110461358A (zh) | 2017-03-31 | 2019-11-15 | 公立大学法人奈良县立医科大学 | 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物 |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| AU2018361430B2 (en) | 2017-11-01 | 2025-08-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody variant and isoform with lowered biological activity |
| CA3093729A1 (en) | 2018-03-15 | 2019-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
| GB201820006D0 (en) * | 2018-12-07 | 2019-01-23 | Lifearc | Humanised anti-IL17BR antibody |
| CN114728064B (zh) | 2019-11-20 | 2025-05-06 | 中外制药株式会社 | 含抗体制剂 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) * | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) * | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU725609C (en) * | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| US6262238B1 (en) * | 1997-01-14 | 2001-07-17 | Roche Diagnostic, Gmbh | Process for modifying the stability of antibodies |
| US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| PE20021080A1 (es) * | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
| US20040028685A1 (en) * | 2002-05-10 | 2004-02-12 | Kinch Michael S. | EphA2 monoclonal antibodies and methods of use thereof |
| EP3263596A1 (en) * | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| KR100872210B1 (ko) * | 2003-04-23 | 2008-12-05 | 메다렉스, 인코포레이티드 | 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체 |
| WO2005035575A2 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
-
2005
- 2005-06-24 US US11/165,023 patent/US20060019342A1/en not_active Abandoned
- 2005-06-24 WO PCT/US2005/022738 patent/WO2006004663A2/en not_active Ceased
- 2005-06-24 AU AU2005259992A patent/AU2005259992A1/en not_active Abandoned
- 2005-06-24 CA CA002572133A patent/CA2572133A1/en not_active Abandoned
- 2005-06-24 EP EP05788064A patent/EP1773391A4/en not_active Withdrawn
- 2005-06-24 JP JP2007518346A patent/JP2008504289A/ja not_active Withdrawn
-
2010
- 2010-02-16 US US12/706,264 patent/US20100145028A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008504289A5 (https=) | ||
| Shi et al. | Latent TGF-β structure and activation | |
| Nemčovičová et al. | Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions | |
| FI3715372T3 (fi) | Suuren affiniteetin humaaneja vasta-aineita ihmisen IL-4-reseptorille | |
| JP7382383B2 (ja) | 産生細胞株エンハンサー | |
| Wang et al. | The HMGB1 acidic tail regulates HMGB1 DNA binding specificity by a unique mechanism | |
| Laitinen et al. | Chicken avidin-related proteins show altered biotin-binding and physico-chemical properties as compared with avidin | |
| JP2014527802A5 (https=) | ||
| JP2005120106A5 (https=) | ||
| JP2017509335A5 (https=) | ||
| Ryseck et al. | Characterization of elements determining the dimerization properties of RelB and p50 | |
| Salier | Chromosomal location, exon/intron organization and evolution of lipocalin genes | |
| Herbert | The ancient Z-DNA and Z-RNA specific Zα fold has evolved modern roles in immunity and transcription through the natural selection of flipons | |
| BR112014025693A2 (en) | recombinant production method of polypeptides in prokaryotic cells | |
| Shan et al. | Generation and characterization of an IgG4 monomeric Fc platform | |
| Hennicke et al. | Transient pentameric IgM fulfill biological function—Effect of expression host and transfection on IgM properties | |
| Simm et al. | Distribution and evolution of stable single α-helices (SAH domains) in myosin motor proteins | |
| KR20130088845A (ko) | 인간 사이토메갈로 바이러스 감염의 검출 방법 | |
| Aguayo-Ortiz et al. | Thermodynamic stability of human γD-crystallin mutants using alchemical free-energy calculations | |
| McKown et al. | Conserved regional 3′ grouping of rare codons in the coding sequence of ocular prosecretory mitogen lacritin | |
| Nagibina et al. | Intrinsic disorder-based Design of Stabilizing Disulphide Bridge in GO protein | |
| Chen et al. | Optimization on Fc for improvement of stability and aggregation resistance | |
| JP6753143B2 (ja) | ＦｃγＲＩＩａをコードするポリヌクレオチド及びＦｃγＲＩＩａの製造方法 | |
| Madhumalar et al. | Dimerization of the core domain of the p53 family: a computational study | |
| WO2007058267A8 (ja) | 新規タンパク質及びそれをコードする遺伝子 |